Elite Pharmaceuticals Inc (ELTP)

[imanjen13]

Vigabatrin, which is used for the treatment of epilepsy in infants, has very serous effects including a risk of loss of vision. Before it can be commercialized and marketed, Pyros must submit a successful Risk Evaluation and Mitigation Strategy to make sure Doctors and potential users are aware of the serious dangers and the need for constant monitoring that it is not harming the patient.

This issue is much more serious than the dispute over the Generic name of Vigpoder viz a viz Vigadrone which Upsher Smith may decide not to appeal.

Considering the possibility of legal liability, Elite probably considers the high cost of the drug to by worth the risk. For shareholders it is just another iron in the fire.